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Background: Opticin (OPTC) is a member of the small leucine-rich proteoglycan (SLRP) family and is localized
particularly in certain extracellular matrices. We have previously reported the unique expression of another SLRP,
fibromodulin (FMOD) in the leukemic cells of patients with chronic lymphocytic leukemia (CLL). OPTC is located in
the same region as FMOD on chromosome 1 (1q32.1). Cluster up-regulation of genes may be observed in
malignancies and the aim of the present study was to analyze the expression of OPTC in CLL cells.
Methods: The expression of OPTC was tested by RT-PCR and realtime qPCR in PBMC from CLL patients, other
hematological malignancies and healthy controls. The presence of OPTC protein, and its subcellular localization, was
investigated using fractionation methods where the obtained lysate fractions were analyzed by Western blotting.
Deglycosylation experiments were performed to investigate the glycosylation status of the CLL OPTC.
Results: OPTC was expressed at the gene level in all patients with CLL (n = 90) and in 2/8 patients with mantle cell
lymphoma (MCL) but not in blood mononuclear cells of healthy control donors (n = 20) or in tumor samples from
nine other types of hematological malignancies. OPTC was detected by Western blot in all CLL samples analyzed
(n = 30) but not in normal leukocytes (n = 10). Further analysis revealed a CLL-unique unglycosylated 37 kDa core
protein that was found to be located preferentially in the cell nucleus and endoplasmic reticulum (ER) of the
CLL cells.
Conclusions: A 37 kDa unglycosylated OPTC protein was detected in ER and in the nucleus of CLL cells and not in
healthy control donors. The function of this OPTC core protein remains unclear but its CLL-specific expression and
subcellular localization warrants further investigations in the pathobiology of CLL.
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Chronic lymphocytic leukemia (CLL) is the most com-
mon adult leukemia and has a highly variable clinical
course. It is characterized by an accumulation of B cells
expressing the cell surface antigens CD5, CD19, CD23,
CD20dim and sIgMdim. In the last years, there has been an
increased interest to characterize cellular and molecular* Correspondence: eva.mikaelsson@ki.se
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distribution, and reproduction in any mediummechanisms involved in the CLL biology with the aim to
develop new targeted therapeutics [1,2].
In a study by Klein et al., the global gene expression
profiling of CLL cells showed an increased expression of
the extracellular matrix (ECM) protein fibromodulin
(FMOD) [3]. FMOD is a member of the small leucine-
rich proteoglycan (SLRP) family and is normally ex-
pressed in collagen-rich tissues. We demonstrated that
FMOD was expressed at the gene and protein levels in
CLL and mantle cell lymphoma (MCL) cells [4]. The un-
expected finding of an ECM protein in leukemic cellstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 OPTC gene expression (RT-PCR) in isolated tumor
cells from patients with various types of hematological
malignancies and normal leukocyte subsets of healthy
control donors
Cell source No. of positive
cases/total no.
Chronic lymphocytic leukemia (PBMC) 90/90
Mantle cell lymphoma (PBMC) 2/8
Pre B-ALL (PBMC) 0/1
Chronic myelogenous leukemia (PBMC) 0/7
Acute myelogenous leukemia (PBMC) 0/7
Prolymphocytic leukemia (B and T cell types) (PBMC) 0/3
Hairy cell leukemia (PBMC) 0/2
Lymphoplasmacytoid lymphoma (PBMC) 0/2
Multiple myeloma (BMMC) 0/6
Follicular lymphoma (PBMC*) 0/2
Normal healthy PBMC (lymphocytes and monocytes) 0/20
Normal blood T cells** 0/3
Normal blood B cells*** 0/3
PBMC peripheral blood mononuclear cells, BMMC bone marrow mononuclear
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members might be expressed in CLL cells.
Cluster/locus upregulation of genes has been reported
in malignant diseases [5]. FMOD is located on chromo-
some 1q32.1 [6], adjacent to two other members of the
SLRP family: proline/arginine-rich end leucine-rich re-
peat protein (PRELP) and opticin (OPTC). OPTC was
first described as a 90 kDa homodimeric glycoprotein in
bovine vitreous [7,8] but in addition, opticin glycopro-
tein has been detected in cartilage [9] and OPTC mRNA
expression has been noted in cartilage, brain, ligament,
testis, muscle and skin [7,10-12]. OPTC interacts with
collagen, growth hormone and heparin sulphate and
may play a role in modulating cell anchorage, growth
factor sequestration as well as regulation of angiogenesis
[13-16].
In this study we analyzed the expression of OPTC in
CLL cells as an extension to our previous studies on
FMOD [4] in CLL. We found that OPTC was expressed
as an unglycosylated core protein in the nucleus and ER
of CLL cells and not in healthy control donors or other
hematological malignanices.cells.
* Severe lymphocytosis.
** Purity >70%, *** purity >90%.
Figure 1 OPTC gene expression (RT-PCR) in PBMC of CLL (n = 5)
and healthy controls donors (n = 2). β-actin was used to verify the
integrity of synthesized cDNA. Marker is a 100 bp DNA ladder.Results
OPTC gene expression
The expression of OPTC mRNA in tumor cells from
CLL patients and nine other types of hematological malig-
nancies as well as PBMC and leukocyte subsets from
healthy controls donors was tested by RT-PCR. PBMC
of all CLL patients (n = 90) expressed OPTC at the
mRNA level irrespective of clinical phase (non-progressive /
progressive). OPTC was also expressed in tumor cells of
some MCL patients (2/8) but not in tumor cells from
other hematological malignancies e.g. AML, CML, PLL,
HCL, FL, lymphoplasmacytoid lymphoma, MM, and
ALL. Neither was OPTC detected in normal PBMC
(n = 20) or isolated B cells (purity >90%, n = 3) and
T cells (purity > 70%, n = 3) of healthy control donors
(Table 1; Figure 1). OPTC was not expressed in any of
the six CLL cell lines tested (EHEB, I83,Wa, CII, 232B4,
PGA) (data not shown).
The relative expression of OPTC was quantified in re-
lation to the housekeeping gene GAPDH using qPCR.
The expression of OPTC was significantly higher in CLL
patients (n = 30) compared to healthy control donors
(n = 12) (p < 0,0001). Comparing CLL samples from pro-
gressive and non-progressive patients showed a higher
relative expression of OPTC in each of the two groups
compared to healthy donors (p < 0,0001 respectively).
The mean relative expression of OPTC appeared to be
somewhat higher in progressive (n = 16) than non-
progressive (n = 14) CLL patients but the difference was
statistically not significant (Figures 2A and 2B).Specificity of anti-OPTC antibodies
The molecular weight by SDS-PAGE of the normal
glycosylated OPTC protein varies between 45–50 kDa
[7,11]. The specificity of our C-terminal anti-OPTC pAb
was tested in Western blot against recombinant bovine
OPTC and human OPTC expressed in E.coli and TM3
mouse cells. Cells transfected with the vector alone were
used as a negative control. Bovine OPTC was recognized
as a 45–50 kDa band (Figure 3A), corresponding to the
mature, glycosylated OPTC protein [11]. Human OPTC
expressed in the TM3 mouse cell line, had a molecular
mass of 48 kDa (Figure 3A) while OPTC expressed
Figure 2 Quantitative OPTC gene expression (q-PCR) in PBMC of CLL patients (non-progressive/progressive) and healthy controls.
A The relative expression of OPTC was significantly higher in CLL patients (n = 30) compared to healthy control donors (n = 12) (p < 0,0001).
B The relative expression of OPTC was higher in progressive (n = 16) and non-progressive (n = 14) patients compared to healthy donors
(p < 0,0001). There was no significant difference in OPTC expression between non-progressive and progressive CLL. Relative expression of OPTC
was calculated using the ΔCt method and GAPDH as reference gene.
A B
Figure 3 Western blot analyses to validate the specificity of the
own-produced anti-OPTC antibody. The precursor OPTC gene
was cloned into pcDNA3.1+ vector and transfected into A) mouse
TM3 cell line and B) E. coli JM109. Lane 1: Lysate of cells transfected
with the vector alone (negative control). Lane 2: Lysate of cells
transfected with the OPTC construct. Lane 3: bovine OPTC
produced in HEK-293 cells. Our C-terminal pAb detected a 48 kDa
human OPTC expressed in TM3 cells, a 37–38 kDa OPTC produced in
bacteria JM109 and a 45–50 kDa recombinant bovine OPTC.
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(Figure 3B).
OPTC protein expression in CLL cells
PBMC of CLL patients (n = 30) were tested for OPTC
protein expression by Western blot. Leukemic cell ly-
sates were prepared by a 2-step method giving rise to
two fractions. In the lower, Triton X-resistant fraction
containing membrane and organelle proteins [17], a
37 kDa band was seen in all CLL patients (n = 30) irre-
spective of clinical phase (non-progressive / progressive)
but not in any of the healthy controls (n = 10) (Figure 4).
The 37 kDa band was recognized both by the C-
terminal and the N-terminal pAbs indicating that the
37 kDa protein was probably not a degradation or cleavage
product. No OPTC band could be detected in the upper
fraction, holding cytosolic proteins (data not shown).
To ensure equal loading of samples, the membranes
were stripped and re-probed with an anti-β-actin mAb
(Sigma). In the upper fraction, a band of 42 kDa was
detected in CLL patients as well as in healthy controls
(data not shown). In the Triton-X resistant fraction,
multiple β-actin bands (possible actin turnover cleavage
products [18] were noted in the healthy controls
whereas CLL samples showed a single 42 kDa band
(Figure 4, lower panel).
Subcellular fractionation
To further analyze the cellular localization of OPTC in
CLL cells, we used a four-step lysis procedure in which
the CLL cell proteins were fractionated into cytosolic,
membrane, nuclear and cytoskeletal proteins respect-
ively. The CLL-specific 37 kDa OPTC band was detectedin the membrane as well as in the nuclear fractions. In
addition, a band of slightly smaller molecular weight was
detected in the cytosolic fraction (Figure 5A). This band
was not detected by the N-terminal pAb and is possibly
a cleavage product [8].
Figure 4 Western blot of cell lysates from CLL patients and
healhty control donors. The membrane/organelle fraction
from non-progressive (n = 4) and progressive (n = 4) CLL patients
and from one healthy control. Upper panel: a rabbit anti-
C-terminal OPTC pAb detecting a 37 kDa band in the
membrane/organelle fraction of CLL cells but not in healthy
donor PBMC. Lower panel: The same membrane stripped and
re-probed with an anti-β-actin mAb. Multiple bands were
detected in the healthy control while in CLL patients a single
42 kDa band was noted.
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A nuclei protein isolation kit (separating nuclear pro-
teins from non-nuclear proteins) was used to analyze
nuclear localization of CLL OPTC. The 37 kDa CLL
OPTC was detected in the nuclear fraction while the
non-nuclear fraction was negative (Figure 5B).A
Figure 5 Western blot of the cell fractionation experiments A) 4-step
anti-OPTC pAb, a 37 kDa band was detected in membrane, nuclear, and ER
molecular weight (possible degradation/cleavage fragment) was detectedEndoplasmic reticulum isolation / localization
An endoplasmic reticulum isolation kit was used to iso-
late ER proteins from CLL cells. The 37 kDa CLL related
OPTC was detected in the 1000 g and 100 000 g centri-
fugation pellets, representing the nuclei and ER fraction
respectively. As in the 4-step lysis described above, a
weak band of smaller molecular weight (possibly a clea-
vage product) was noted in the supernatant (12000 g +
100000 g) representing cytoplasmic proteins (Figure 5C).
Deglycosylation of the OPTC protein
To explore structural properties of the 37 kDa OPTC in
CLL, chemical deglycosylation was performed using
OPTC expressed in yeast and a recombinant bovine
OPTC produced in 293-EBNA cells. Yeast-derived OPTC
was seen as smeary bands at 45–50 kDa and 70–120 kDa.
After 30 min of TFMS treatment, a 39 kDa band
appeared while the 45–50 kDa bands had disappeared.
The 70–120 kDa bands were reduced in intensity and to
a size of 100 kDa. The deglycosylation procedure was
enhanced by the use of TFMS and anisole for 1 and
3 hours. After 3 h, the 100 kDa band completely
disappeared and the intensity of the 39 kDa band in-
creased. The 39 kDa band may represent completely
deglycosylated OPTC (Figure 6A). Also after 3 h, a weak
band of 30 kDa appeared, which is believed to be a deg-
radation/cleavage product [8].
Treatment of recombinant bovine OPTC using TFMS
for 30 min resulted in the reduction of the protein size
from 45–48 kDa to 40–42 kDa (Figure 6B).
Discussion
In the present study we demonstrated that OPTC, a
member of the SLRP family, was overexpressed in
leukemic cells from CLL and MCL patients. Tumor cellsB C
lysis, B) nuclei isolation and C) ER isolation. Using the C-terminal,
fractions (lanes A2, A3, B2, C1 and C3). A band of slightly smaller
in the cytosol fractions (lanes A1 and C2).
Figure 6 Western blot of human and bovine OPTC after
chemical deglycosylation by TMFS. A) recombinant human OPTC
produced in yeast and B) recombinant bovine OPTC. Western blot
was performed using a C-terminal anti-OPTC pAb. Lane 1: Untreated
recombinant OPTC. Lane 2: Recombinant OPTC treated with TFMS
for 30 min. Lanes 3 and 4: Recombinant OPTC treated with TFMS
and anisole for 1 and 3 h, respectively. Complete removal of the
carbohydrate structures yielded a 39 kDa and a 40–42 kDa band in
the human and bovine OPTC, respectively.
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healthy donors did not express OPTC when tested by
RT- and qPCR. Furthermore, an unglycosylated 37 kDa
OPTC protein was found to be expressed in CLL cells
but not in normal leukocytes.
Normal OPTC is a glycosylated protein that runs at
45–50 kDa on SDS-PAGE gels and is secreted into the
ECM compartment of various tissues. The expression
has mostly been associated with the eye but has also
been identified in other tissues including brain, skin,
ligament and cartilage [7,10-12]. In the vitreous humour
of the eye extracellular OPTC protein has been shown
to be anti-angiogenic by binding to collagen and
inhibiting α2β1 and α1β1 integrin-mediated endothelial
cell adhesion to the collagen; there is also evidence that
it binds growth hormone and may modulate its function
[14-16].
There are several reports on SLRPs being over-
expressed in cancer [19-22]. They may be expressed
either by the tumor cells or by non-cancerous fibro-
blasts in the surrounding matrix. Several in vitro and
in vivo studies suggest that SLRPs may act as anta-
gonists of tumor growth, metastatic spreading and
angiogenesis [23].In this study, OPTC was expressed in the leukemic
cells of all CLL patients and in the lymphoma cells of
some patients with MCL. There are few reports con-
necting OPTC expression to cancer. In ciliary body
tumor cells (originating from the eye), OPTC was shown
to be downregulated compared to normal ciliary body
epithelium [24]. In a panel of breast cancer cell lines,
OPTC expression was induced by adenoviral transfec-
tion, which suppressed proliferation, increased apoptosis
and reduced migration [25].
We have previously reported a similar expression pat-
tern for FMOD, a closely related member of the SLRP
family [4]. FMOD, OPTC and the other SLRPs are se-
creted proteins that bind to cell membrane receptors or
ECM proteins. However, there are reports of SLRPs with
intracellular localization, both in normal and in tumor
tissues. FMOD was detected in the cytoplasm of human
epidermal keratinocytes [26]. Lumican, another member
of the SLRP family, was localized in the cytosol of lung
as well as colorectal cancer cells [27].
Using the three cell fractionation kits, OPTC was
detected in the nuclear and ER fractions resp. of the
CLL cells. The Nuclei isolation kit detected the 37 kDa
OPTC in the nuclear fraction. No OPTC protein was
noted in the non-nuclear fraction (where the ER OPTC
might have been seen) which may be due to large vol-
ume of the non-nuclear fraction diluting the OPTC pro-
tein. As the focus was on the nuclear OPTC, we did not
concentrate the non-nuclear fraction.
Nuclear localization has been observed for some
SLRPs (e.g. PRELP, biglycan and decorin) where they
might participate in various nuclear processes [28-30].
Decorin was noted in the cytoplasm as well as in the nu-
clei of human oral cancer biopsies and cell lines [30].
Several decorin variants were found, one of them had a
molecular weight corresponding to a decorin protein
core without post-translational modifications. The iden-
tified nuclear decorin was suggested to play a role in mi-
gration and invasion of the malignant cells [31].
Glycosylation is an important process affecting folding,
stability and functions of a protein. In normal tissues,
SLRPs show varying degrees of glycosylation, which may
differ between species and are of importance for tissue
distribution and functions [32].
In tumors, the glycosylation of SLRPs may vary be-
tween and within individual tumors [21,33-35]. The dif-
ference between normal human OPTC (45–50 kDa) and
CLL-derived OPTC (37 kDa) may be due to differen-
ces in glycosylation. Complete deglycosylation of yeast-
derived human OPTC yielded a 39 kDa OPTC, slightly
larger than the OPTC detected in CLL cells and the re-
combinant human OPTC derived of bacteria (37 kDa).
The small difference in the molecular weight might be
due to other modifications of the yeast derived protein.
Table 2 Clinical characteristics of the CLL patients (n = 90)
Characteristic Frequency (%)
Sex
Male 70
Female 30
Age, y
40–49 7
50–59 7
60–69 38
70–79 39
80–89 10
Clinical phase
Progressive * 47
Non-progressive * 53
Rai Stage
O 39
I 26
II 7
III 26
IV 3
Treatment
Previously treated ** 33
Previously untreated *** 67
* For definition, see ref [43].
** Test performed at relapse / progression prior to initiation of salvage therapy.
*** Among 60 untreated patients, 33 were indolent and 27 were progressive/
symptomatic but tested prior to first-line therapy.
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OPTC protein without side-chain glycan modifications.
A 37 kDa OPTC protein with no post-translational mo-
difications has been found in normal rat [11].
The 37 kDa CLL-OPTC was detected both by a C-
and a N-terminal anti-OPTC antibody, indicating that
this protein may not be a degradation or cleavage prod-
uct. Thus, CLL cells seemed to express an unmodified
protein backbone.
Regardless of glycosylation, the core protein of several
SLRPs may express binding sites for interactions with
other proteins, e.g. collagen, fibronectin, TGF-β, TNF-α,
epidermal growth factor receptor (EGFR) and integrin
receptors [36-41]. When coated on Transwell® chambers,
recombinant lumican core protein was shown to bind
and inhibit cell migration of α2β1 integrin bearing cells
[42]. Systemic delivery of decorin protein core, down-
regulated the epidermal growth factor receptor (EGFR),
leading to growth inhibition as well as increased apop-
tosis of squamous cell carcinoma xenografts in mice
[41]. Whether the 37 kDa core OPTC protein in CLL
has similar capabilities needs to be further studied.
The biological function of OPTC in CLL is not clear
but might resemble those of other SLRPs in malignant
cells, such as lumican [42], or decorin [31]. The specific
and unique expression of the 37 kDa core OPTC protein
in all patients may indicate a functional role. The spe-
cific expression of two other proteoglycans, FMOD [4]
and PRELP (to be published) in CLL might support a
role of proteoglycans in CLL. Functional characterization
of the CLL-associated OPTC variant may assist in ex-
ploring the role of OPTC in the pathobiology of CLL.
Conclusions
We demonstrate in this study the unexpected expression
of the ECM protein OPTC in all CLL patients and some
patients with MCL. The detected OPTC protein was lo-
calized to the nucleus and ER of the leukemic cells and
had a molecular weight corresponding to an unglycosy-
lated core protein. The unique expression of an ungly-
cosylated OPTC with aberrant localization in CLL cells
may suggest involvement in the pathobiology of CLL.
Materials and methods
Patients and controls
The diagnosis and clinical staging of CLL (progressive/
non-progressive) and other hematological malignancies
was established using the WHO classification of hema-
topoetic and lymphoid malignancies and the IWCLL cri-
teria [43,44]. The CLL patients included 63 men and 27
women who were 44–87 years old at the time of diag-
nosis. Most patients (77%) were in the age range of
60–79 years. The distribution of Rai stages was as fol-
lows: 35 patients (39%) stage 0, 23 patients (26%) stage I,6 patients (7%) stage II, 23 patients (26%) stage III and 3
patients (3%) stage IV. Progressive disease was observed
in 42 patients (47%), and non-progressive disease in 48
patients (53%). 60 patients (67%) were untreated while
30 patients (33%) were previously treated (Table 2). The
healthy control group consisted of 12 men and 8 women,
at the age range of 44–74 years.
Heparinized blood containing tumor cells was col-
lected from patients with CLL (n = 90), MCL (n = 8),
hairy cell leukemia (HCL) (n = 2), B-cell prolymphocytic
leukemia (B-PLL) (n = 2), T-cell prolymphocytic leu-
kemia (T-PLL) (n = 1), chronic myelogenous leukemia
(CML) (n = 7), acute myelogenous leukemia (AML)
(n = 7), pre B-cell acute lymphoblastic leukemia (pre
B-ALL) (n = 1), follicular lymphoma (FL) (n = 2) and
lymphoplasmacytoid lymphoma (n = 2). Bone marrow
tumor cells were obtained from patients with multiple
myeloma (MM) (n = 6). Blood was also drawn from
healthy control donors (n = 20).
This study was approved by the regional ethics com-
mittee (www.epn.se) and all samples were collected with
informed consent of the patients.
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Peripheral blood mononuclear cells (PBMC) from nor-
mal donors and leukemic cells from blood and bone
marrow were isolated using Ficoll-Paque Plus (GE
Healthcare, Buckinghamshire, UK) density-gradient cen-
trifugation. T and B lymphocytes were purified by ne-
gative selection using MACS beads (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufac-
turer’s instructions. The purity of the isolated popula-
tions was tested by direct immunofluorescence using
monoclonal antibodies against CD3, CD19, and CD14
(BD Biosciences, San Jose, CA, USA). The purity was >
90% for normal B cells and > 70% for normal T cells.
CLL cell lines
Six cell lines of CLL origin were also studied. The cell line
EHEB was obtained from the German collection of Micro-
organisms and Cell Cultures (DSMZ, Braunschweig,
Germany) while the others (I83-E95, 232-B4, WaC3-
CD5, CII and JCA) [45,46] were a kind gift from pro-
fessor Anders Rosén (Linköping University, Sweden)
and professor Kenneth Nilsson (Uppsala University,
Sweden). The cell lines were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum
(FBS), L-glutamine (2 mM), penicillin (100 U/mL), and
streptomycin (100 μg/mL) (Gibco, Paisley, Scotland).
RT-PCR and quantitative PCR (q-PCR) amplification of
OPTC mRNA
Total RNA was extracted from tumor cells and normal
PBMCs using PureLinkTM RNA mini kit (Ambion,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. First strand cDNA was synthesized using
2 μg total RNA in 20 μL reaction mixture consisting of
4 μL 5× reaction buffer, 1 μL dNTP (10 mM), 1,5 μL
100 uM dithiothreitol (DTT) 1 μL 10 pmol/mL random
hexamer (N6), and 200 U M-MLV reverse transcriptase
(Gibco). The mixture was incubated at 42°C for 50
minutes. PCR amplification was performed using OPTC-
specific primers TTGACCTCTCCAACAACCTC (sense)
and GGTCACAGAAGACGTCTCTC (antisense) [9]. A
25 μL reaction mixture was prepared using 2,5 μL
10× buffer, 3 μL 25 mM MgCl2, 1,5 μL dNTP (10 mM), 5
pmol of each primer, and 1 U Ampli-Taq Gold DNA poly-
merase (Perklin-Elmer/Applied Biosystems, Boston, MA,
USA). PCR was initiated by 10 min at 95°C, followed by
38 cycles at 94°C for 60 seconds and 60°C for 90 seconds
leading to a 327 bp amplicon. PCR products were visua-
lized by running agarose gel electrophoresis containing
ethidium bromide.
Quantitative q-PCR was performed using three
Taqman gene expression assays for OPTC (Applied
Biosystems, assay ID# Hs01057359_m1, Hs01057360_m1
and Hs01057361_m1). PCR reactions consisting of 1 μLcDNA, 1× TaqMan® Universal PCR Master Mix, 0.2 μM
TaqMan® primer-probe mix were carried out in final
volumes of 20 μL using an ABI Prism 7900 Sequence De-
tection System (Applied Biosystems). Reactions were initi-
ated with 10 min incubation at 95°C followed by 40 cycles
of 95°C for 15 sec and 60°C for 60 sec. The analysis was
based on individual samples run in triplicates for each of
the three OPTC assays, of which one mean Ct value was
calculated. The expression of OPTC was then normalized
against the housekeeping gene GAPDH (Applied Bio-
system assay #Hs02758991_g1) and relative quantities
were determined by the comparative Ct (ΔCt) method.
Production of OPTC protein in bacteria, yeast, and
mammalian cells
Due to lack of commercially available OPTC protein, we
established an expression system based on a human full-
length precursor OPTC transcript that was amplified by
PCR using a pool of CLL cDNA from 10 patients as
template. PCR amplification was performed using OPTC
specific primers GAATTCATGAGGCTCCTGGCTTT
CCTGAGTC (sense) and GCGGCCGCTCTACGTGA
AGCGGCCGATGG (antisense). PCR reaction mixture
was prepared using 2.5 μl of 10× buffer, 2 μl of 25 mM
MgCl2, 1.5 μl dNTPs (10 mM), 5 pmol of each primer
and 1 unit of Ampli-Taq Gold DNA polymerase (Perkin-
Elmer/Applied Biosystems). PCR was initiated by 1 cycle
at 95°C for 10 min, followed by 35 cycles at 92°C; 30 sec,
60°C; 30 sec, and 72°C; 90 sec. The PCR products were
cloned into pGEM-T easy vector (Promega, Madison,
WI, USA) and subcloned into EcoRI-NotI site of
pcDNA3.1+ vector (Invitrogen, Carlsbad, CA, USA) for
mammalian expression. For bacterial expression, this
vector was slightly modified by insertion of ribosome
binding sequences (RBS). The EcoRI-NotI sequence was
also subcloned into pGAPZα-A vector for yeast (P. pas-
toris) expression (Invitrogen). The recombinant plasmids
were selected for sequencing. For bacterial expression,
an in-frame clone was selected and transformed into E.
coli strain JM109. The bacteria culture was harvested
after 24 h and a bacteria pellet was collected by centrifu-
gation. A small volume of phosphate buffered saline
(PBS) was added to the pellet and cell lysate was pre-
pared by 5× 15 sec of sonication. The yeast supernatant
was collected after 72 h of culture and concentrated up
to 30 times using Amicon Ultra-15 Centrifugal Filter
Units (Millipore Corporation, Bedford, MA, USA). For
expression of OPTC in mammalian cells, the EcoRI-
NotI pcDNA3.1+ vector was transiently transfected into
mouse TM3 cell line. After 48 h, cell lysate was prepared
as described below. Yeast supernatant, bacteria and
TM3 cell lysate were subjected to Western blot.
Recombinant bovine OPTC, produced in 293-EBNA
cells, was prepared as described previously [8,13].
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(HomoloGene, http://www.ncbi.nlm.nih.gov/) and served
as a positive control in Western blot and deglycosylations
experiments (see below).
Anti-OPTC polyclonal antibodies
In the absence of commercially available anti-OPTC
antibodies recognizing OPTC in CLL, a rabbit anti-
OPTC polyclonal antibody (pAb) was generated against
a 12-mer synthetic peptide (CDPEEHKHTRRQ) pur-
chased from Thermo Electron Corporation GmbH (Ulm,
Germany) corresponding to the carboxy-terminal
(C-terminal) part of human OPTC [11]. The antibody
was purified by affinity chromatography. A previously
characterized rabbit anti-OPTC pAb generated against the
human N-terminal peptide VLNPDNYGEVIDLSNYEELT
DYGDQLPEVK of OPTC was also used [8].
Cell lysate
Cell lysates were prepared as described [17] with minor
modifications from PBMC of CLL patients (n = 30) and
healthy controls (n = 10) as well as the transfected cell
line TM3. 50×106 cells were lysed in 1 mL of buffer
containing 0.2% Triton-X, 130 mM HEPES, 4 mM
MgCl2, 10 mM EGTA with 2% proteinase inhibitor cock-
tail (Sigma, St Louis, MO, USA). After 1 h incubation
on ice, lysates were centrifuged at 2500 rpm for 5 min
and the soluble fraction (“upper fraction” holding
cytosollic proteins) was collected. The Triton-X resistant
pellet was dissolved in 1× NuPAGE LDS Sample Buffer
(Invitrogen) and sonicated for 3x15 sec (“lower fraction”
containing proteins from membrane and inner orga-
nelles). The protein concentration of the two fractions
was measured by Bio-Rad Protein Assay according to
the manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA, USA) and the samples were subjected to
Western blot.
Subcellular fractionation
To further analyze the cellular localization of OPTC in
CLL cells, proteins were extracted according to the
4-step procedure of Qproteome Cell Compartment Kit
(Qiagen, Hilden, Germany) isolating cytosolic, mem-
brane, nuclear and cytoskeletal proteins, respectively.
Briefly, 50x106 PBMC of CLL patients (n = 8) were
lysed in extraction buffer 1 for 10 min at 4°C. After cen-
trifugation at 1000 g for 10 min, the supernatant was
collected as the “cytosolic fraction”. The remaining pellet
was resuspended in extraction buffer 2 for 30 min at
4°C. After centrifugation at 6000 g for 10 min, su-
pernatant was collected as the “membrane fraction”.
Benzonase buffer was added to the remaining pellet
and incubated for 15 min incubation at room tempe-
rature, followed by addition of extraction buffer 3 andincubation for 10 min at 4°C. After centrifugation at
6800 g for 10 min, the supernatant was collected as the
“nuclear fraction”. The remaining pellet was dissolved in
extraction buffer 4 and collected as the “cytoskeletal
fraction”. The protein concentration of each fraction was
measured by Bio-Rad Protein Assay (Bio-Rad Laboratories)
and the samples were analyzed by Western blotting.
Nuclei isolation
Nuclei EZ Prep Nuclei Isolation kit (Sigma) was used to
analyze nuclear localization of OPTC. Briefly, 50×106
PBMC of CLL patients (n = 8) were lysed in Nuclei EZ
lysis buffer and incubated on ice for 5 minutes. After
centrifugation, the supernatant containing non-nuclear
proteins was collected and concentrated 8× using
Amicon Ultra-15 Centrifugal Filter Units (Millipore
Corp.). The resultant nuclear pellet was washed in Nu-
clei EZ lysisbuffer, centrifuged, resuspended in Nuclei
EZ storage buffer, and sonicated for 3×10 sec. The pro-
tein concentration of both fractions was measured by
Bio-Rad Protein Assay (Bio-Rad Laboratories) and ana-
lyzed by Western blotting.
Endoplasmic reticulum isolation
Endoplasmic Reticulum (ER) Isolation Kit (Sigma) was
used to analyze the localization of OPTC in ER. Briefly,
800x106 PBMC of CLL patients (n = 3) were suspended
in 1× hypotonic isolation buffer and lysed with a Dounce
homogenizer (Sigma). After centrifugation at 1000 g for
10 min, the resultant pellet enriched in cell nuclei [47]
was suspended in 1× sample buffer (Invitrogen) and son-
icated for 3×10 sec. The supernatant was further clari-
fied by centrifugation for 15 min at 12 000 g and then at
100 000 g for 60 min. The final supernatant (holding
cytosolic proteins) was collected and utilized for analysis.
The remaining pellet containing the crude microsomal
fraction, which included the rough and smooth ER, was
suspended in isotonic extraction buffer and homoge-
nized using a pellet pestle (Sigma). The protein concen-
tration of the three fractions was measured by Bio-Rad
Protein Assay (Bio-Rad Laboratories) and analyzed by
Western blotting.
Chemical deglycosylation of the OPTC protein
Trifluoromethanesulfonic acid (TFMS) removes all car-
bohydrates chains from glycoproteins regardless of link-
age and composition [48]. Two sources of recombinant
OPTC protein were used for chemical deglycosylation
with TFMS (Sigma) and anisole (Fluka, Sigma): 1) re-
combinant human OPTC expressed in yeast and 2) re-
combinant bovine OPTC expressed in 293-EBNA cells.
250 μl of 1× OPTC yeast culture and 30 μg of bovine
OPTC were precipitated separately by incubation in
99,7% ethanol at −20°C over night. After centrifugation
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in 95% ethanol, collected by centrifugation and dried in
a vacuum centrifuge for 20 min. Three pellets were pre-
pared for each sample and were added 1) 200 μl TFMS
for 30 min, 2) TFMS/anisole (9:1) for 1 h and 3) TFMS/
anisole (9:1) for 3 h. The samples were kept on ethanol/
dry ice during the addition of TFMS/anisole and on ice
for the remaining incubation time. The reaction was
stopped by adding 2 M Tris base (pH 8) until pH
reached 6. The samples were dialyzed against 10 mM
phosphate buffer for 24 h, concentrated up to 20 times
using Amicon Ultra-15 Centrifugal Filter Units (Millipore
Corp.), and then subjected to Western blot.Western blot
Cell lysate (20 μg), serum (1:50), yeast supernatants, bac-
terial lysate (10 μg) and recombinant bovine OPTC
(0,5 μg) were separated on a 10% NuPAGE Bis-Tris gel
(Invitrogen) at 120 V for 3 h under reducing conditions.
Resolved proteins were transferred onto Immobilon-P
PVDF membrane (Millipore Corp.) in a Mini-Transblot
Cell (Invitrogen). Non-specific antibody binding was
blocked by incubating the membranes at room tempera-
ture for 1,5 h with 5% non-fat milk (Semper, Stockholm,
Sweden) in PBS plus 0.05% Tween 20 (PBS-T). The
membranes were incubated with 10 μg/ml of rabbit anti-
OPTC pAbs (C- and N-terminal) over night at +4°C and
a secondary horseradish peroxidase (HRP)-conjugated
goat anti-rabbit antibody (DakoCytomation, Glostrup,
Denmark) for 1.5 h at room temperature. Both incuba-
tions were followed by 4 × 15 min washings in PBS-T.
Antibody-reactive bands were visualized using Amersham
Enhanced Chemiluminescence ECL™ system (GE health-
care). All Western blot figures are showing the results of
our anti-OPTC C-terminal pAb but all results were con-
firmed by the anti-OPTC pAb provided by professor
Bishop.
As a control for the amount of protein loaded, mem-
branes were stripped of bound antibody using a buffer
containing 62.5 mM Tris–HCl, 2% SDS, 100 mM
Mercaptoethanol (Sigma) at 50°C for 30 min with gentle
agitation. After 3×15 min washing in PBS-T, the mem-
branes were re-probed with 2.5 μg/ml of a mouse anti-β
-actin monoclonal antibody (mAb) (Sigma).Statistical analysis
The results of OPTC mRNA expression using qPCR are
shown as mean ± SEM and statistical analysis was per-
formed with a T-test or Anova multivariant analysis to-
gether with post hoc Tukey test.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
Contribution: EM designed and performed most of the experiments,
analyzed the data and wrote the paper. HR designed the project. HM
provided clinical material, designed the study and wrote the paper.
AÖ provided clinical material, analyzed the results and wrote the paper.
FS contributed in designing the study. PB and ZT-F produced antibodies and
recombinant opticin. MJ-T, AM, JM and MA produced antibodies. All authors
read and approved the final manuscript.
Acknowledgements
The study was supported by grants from the Swedish Cancer Society, the
Stockholm County Council, the Torsten and Ragnar Söderberg Foundation,
the Cancer Society in Stockholm, the King Gustaf V Jubilee Fund, the
Swedish Research Council/SIDA/SAREC, the Iranian Ministry of Health and
Medical Education, the Cancer and Allergy Foundation, and the Karolinska
Institute Foundations. We would like to acknowledge support from
Manchester Biomedical Research Centre. We thank Ms Ingrid Eriksson and
Ms Barbro Näsman for technical assistance and Ms. Leila Relander for
secretarial help.
Author details
1Immune and Gene Therapy Lab, CCK, Department of Oncology-Pathology,
Karolinska Institute, Stockholm, Sweden. 2Departments of Oncology
(Radiumhemmet) and Hematology, Karolinska University Hospital Solna,
Stockholm, Sweden. 3Monoclonal Antibody Research Center, Avicenna
Research Institute, ACECR, Tehran, Iran. 4Reproductive Biotechnology
Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
5Department of Immunology, School of Public Health, Tehran University of
Medical Sciences, Tehran, Iran. 6Centre for Hearing and Vision Research,
Institute of Human Development, University of Manchester and Central
Manchester University Hospitals NHS Foundation Trust, Manchester
Academic Health Science Centre, Manchester, UK. 7Department of Biology,
Roudehen Branch, Islamic Azad University, Roudehen, Iran.
Received: 25 June 2013 Accepted: 21 August 2013
Published: 28 August 2013
References
1. Caligaris-Cappio F, Ghia P: Novel insights in chronic lymphocytic
leukemia: are we getting closer to understanding the pathogenesis of
the disease? J Clin Oncol 2008, 26:4497–4503.
2. Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 2008,
371:1017–1029.
3. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman
A, Inghirami G, Cro L, Baldini L, et al: Gene expression profiling of B cell
chronic lymphocytic leukemia reveals a homogeneous phenotype
related to memory B cells. J Exp Med 2001, 194:1625–1638.
4. Mikaelsson E, Danesh-Manesh AH, Luppert A, Jeddi-Tehrani M, Rezvany MR,
Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, et al: Fibromodulin,
an extracellular matrix protein: characterization of its unique gene and
protein expression in B-cell chronic lymphocytic leukemia and mantle
cell lymphoma. Blood 2005, 105:4828–4835.
5. Bieche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretiere
JM, Burlinchon S, Lidereau R, Lazennec G: CXC chemokines located in the
4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 2007,
14:1039–1052.
6. Sztrolovics R, Chen XN, Grover J, Roughley PJ, Korenberg JR: Localization of
the human fibromodulin gene (FMOD) to chromosome 1q32 and
completion of the cDNA sequence. Genomics 1994, 23:715–717.
7. Reardon AJ, Le Goff M, Briggs MD, McLeod D, Sheehan JK, Thornton DJ,
Bishop PN: Identification in vitreous and molecular cloning of opticin, a
novel member of the family of leucine-rich repeat proteins of the
extracellular matrix. J Biol Chem 2000, 275:2123–2129.
8. Le Goff MM, Hindson VJ, Jowitt TA, Scott PG, Bishop PN: Characterization
of opticin and evidence of stable dimerization in solution. J Biol Chem
2003, 278:45280–45287.
9. Monfort J, Tardif G, Roughley P, Reboul P, Boileau C, Bishop PN, Pelletier JP,
Martel-Pelletier J: Identification of opticin, a member of the small
leucine-rich repeat proteoglycan family, in human articular tissues: a
novel target for MMP-13 in osteoarthritis. Osteoarthritis Cartilage 2008,
16:749–755.
Mikaelsson et al. Experimental Hematology & Oncology 2013, 2:23 Page 10 of 10
http://www.ehoonline.org/content/2/1/2310. Pellegrini B, Acland GM, Ray J: Cloning and characterization of opticin
cDNA: evaluation as a candidate for canine oculo-skeletal dysplasia. Gene
2002, 282:121–131.
11. Hobby P, Wyatt MK, Gan W, Bernstein S, Tomarev S, Slingsby C, Wistow G:
Cloning, modeling, and chromosomal localization for a small leucine-rich
repeat proteoglycan (SLRP) family member expressed in human eye.
Mol Vis 2000, 6:72–78.
12. Takanosu M, Boyd TC, Le Goff M, Henry SP, Zhang Y, Bishop PN, Mayne R:
Structure, chromosomal location, and tissue-specific expression of the
mouse opticin gene. Invest Ophthalmol Vis Sci 2001, 42:2202–2210.
13. Hindson VJ, Gallagher JT, Halfter W, Bishop PN: Opticin binds to heparan
and chondroitin sulfate proteoglycans. Invest Ophthalmol Vis Sci 2005,
46:4417–4423.
14. Sanders EJ, Walter MA, Parker E, Aramburo C, Harvey S: Opticin binds
retinal growth hormone in the embryonic vitreous. Invest Ophthalmol Vis
Sci 2003, 44:5404–5409.
15. Le Goff MM, Sutton MJ, Slevin M, Latif A, Humphries MJ, Bishop PN: Opticin
exerts its anti-angiogenic activity by regulating extracellular matrix
adhesiveness. J Biol Chem 2012, 287:28027–28036.
16. Le Goff MM, Lu H, Ugarte M, Henry S, Takanosu M, Mayne R, Bishop PN:
The vitreous glycoprotein opticin inhibits preretinal neovascularization.
Invest Ophthalmol Vis Sci 2012, 53:228–234.
17. Ferreira A, Busciglio J, Caceres A: Microtubule formation and neurite
growth in cerebellar macroneurons which develop in vitro: evidence for
the involvement of the microtubule-associated proteins, MAP-1a,
HMW-MAP2 and Tau. Brain Res Dev Brain Res 1989, 49:215–228.
18. Gourlay CW, Ayscough KR: The actin cytoskeleton: a key regulator of
apoptosis and ageing? Nat Rev Mol Cell Biol 2005, 6:583–589.
19. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, Blaveri E, Baron A, Terris B,
Jones M, Tyson K, Bassi C, Scarpa A, Lemoine NR: Gene expression
profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001,
20:7437–7446.
20. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M: Differential
gene expression in human lung adenocarcinomas and squamous cell
carcinomas. Clin Cancer Res 2002, 8:1127–1138.
21. Lu YP, Ishiwata T, Kawahara K, Watanabe M, Naito Z, Moriyama Y, Sugisaki Y,
Asano G: Expression of lumican in human colorectal cancer cells. Pathol
Int 2002, 52:519–526.
22. Naito Z, Ishiwata T, Kurban G, Teduka K, Kawamoto Y, Kawahara K, Sugisaki
Y: Expression and accumulation of lumican protein in uterine cervical
cancer cells at the periphery of cancer nests. Int J Oncol 2002, 20:943–948.
23. Iozzo RV, Sanderson RD: Proteoglycans in cancer biology, tumour
microenvironment and angiogenesis. J Cell Mol Med 2011, 15:1013–1031.
24. Assheton DC, Guerin EP, Sheridan CM, Bishop PN, Hiscott PS: Neoplastic
transformation of ciliary body epithelium is associated with loss of
opticin expression. Br J Ophthalmol 2007, 91:230–232.
25. Sneddon SF, Telfer BA, Williams KJ, Bishop PN, Stratford IJ, Cowen R:
Opticin: a potent anti-angiogenic/antiproliferative agent for breast
cancer therapy. Breast Cancer Res 2010, 12(1):53. Abstract 2010.
26. Velez-Delvalle C, Marsch-Moreno M, Castro-Munozledo F, Bolivar-Flores YJ,
Kuri-Harcuch W: Fibromodulin gene is expressed in human epidermal
keratinocytes in culture and in human epidermis in vivo. Biochem Biophys
Res Commun 2008, 371:420–424.
27. Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y,
Koizumi K, Nakazawa N, Ishiwata T, Naito Z: Expression and roles of
lumican in lung adenocarcinoma and squamous cell carcinoma.
Int J Oncol 2008, 33:1177–1185.
28. Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece
D, Iansante V, Zazzeroni F, Alesse E, et al: The glycosaminoglycan-binding
domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that
impairs osteoclastogenesis. J Cell Biol 2009, 187:669–683.
29. Liang Y, Haring M, Roughley PJ, Margolis RK, Margolis RU: Glypican and
biglycan in the nuclei of neurons and glioma cells: presence of
functional nuclear localization signals and dynamic changes in glypican
during the cell cycle. J Cell Biol 1997, 139:851–864.
30. Banerjee AG, Bhattacharyya I, Lydiatt WM, Vishwanatha JK: Aberrant
expression and localization of decorin in human oral dysplasia and
squamous cell carcinoma. Cancer Res 2003, 63:7769–7776.
31. Dil N, Banerjee AG: A role for aberrantly expressed nuclear localized
decorin in migration and invasion of dysplastic and malignant oral
epithelial cells. Head Neck Oncol 2011, 3:44.32. Waddington RJ, Roberts HC, Sugars RV, Schonherr E: Differential roles for
small leucine-rich proteoglycans in bone formation. Eur Cell Mater 2003,
6:12–21. discussion 21.
33. Skandalis SS, Theocharis AD, Papageorgakopoulou N, Vynios DH,
Theocharis DA: The increased accumulation of structurally modified
versican and decorin is related with the progression of laryngeal cancer.
Biochimie 2006, 88:1135–1143.
34. Ping Lu Y, Ishiwata T, Asano G: Lumican expression in alpha cells of islets
in pancreas and pancreatic cancer cells. J Pathol 2002, 196:324–330.
35. Sifaki M, Assouti M, Nikitovic D, Krasagakis K, Karamanos NK, Tzanakakis GN:
Lumican, a small leucine-rich proteoglycan substituted with keratan
sulfate chains is expressed and secreted by human melanoma cells and
not normal melanocytes. IUBMB Life 2006, 58:606–610.
36. Schmidt G, Robenek H, Harrach B, Glossl J, Nolte V, Hormann H, Richter H,
Kresse H: Interaction of small dermatan sulfate proteoglycan from
fibroblasts with fibronectin. J Cell Biol 1987, 104:1683–1691.
37. Vogel KG, Koob TJ, Fisher LW: Characterization and interactions of a
fragment of the core protein of the small proteoglycan (PGII) from
bovine tendon. Biochem Biophys Res Commun 1987, 148:658–663.
38. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR,
Border WA, Ruoslahti E: Interaction of the small interstitial proteoglycans
biglycan, decorin and fibromodulin with transforming growth factor
beta. Biochem J 1994, 302(Pt 2):527–534.
39. Tufvesson E, Westergren-Thorsson G: Tumour necrosis factor-alpha
interacts with biglycan and decorin. FEBS Lett 2002, 530:124–128.
40. Goldoni S, Iozzo RV: Tumor microenvironment: Modulation by decorin
and related molecules harboring leucine-rich tandem motifs. Int J Cancer
2008, 123:2473–2479.
41. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan
DJ, Iozzo RV: Decorin protein core inhibits in vivo cancer growth and
metabolism by hindering epidermal growth factor receptor function and
triggering apoptosis via caspase-3 activation. J Biol Chem 2006,
281:26408–26418.
42. Zeltz C, Brezillon S, Kapyla J, Eble JA, Bobichon H, Terryn C, Perreau C,
Franz CM, Heino J, Maquart FX, Wegrowski Y: Lumican inhibits cell
migration through alpha2beta1 integrin. Exp Cell Res 2010, 316:2922–2931.
43. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H,
Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ: Guidelines for the
diagnosis and treatment of chronic lymphocytic leukemia: a report from
the International Workshop on Chronic Lymphocytic Leukemia updating
the National Cancer Institute-Working Group 1996 guidelines. Blood
2008, 111:5446–5456.
44. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J,
Lister TA, Bloomfield CD: The World Health Organization classification of
neoplastic diseases of the haematopoietic and lymphoid tissues: Report
of the Clinical Advisory Committee Meeting, Airlie House, Virginia,
November 1997. Histopathology 2000, 36:69–86.
45. Wendel-Hansen V, Sallstrom J, De Campos-Lima PO, Kjellstrom G, Sandlund A,
Siegbahn A, Carlsson M, Nilsson K, Rosen A: Epstein-Barr virus (EBV) can
immortalize B-cll cells activated by cytokines. Leukemia 1994, 8:476–484.
46. Drexler HG: The Leukemia-Lymphoma Cell Line FactsBook. San Diego:
Academic Press; 2001.
47. el Bahassi M, Hennigan RF, Myer DL, Stambrook PJ: Cdc25C
phosphorylation on serine 191 by Plk3 promotes its nuclear
translocation. Oncogene 2004, 23:2658–2663.
48. Edge AS: Deglycosylation of glycoproteins with
trifluoromethanesulphonic acid: elucidation of molecular structure and
function. Biochem J 2003, 376:339–350.
doi:10.1186/2162-3619-2-23
Cite this article as: Mikaelsson et al.: Opticin, a small leucine-rich
proteoglycan, is uniquely expressed and translocated to the nucleus of
chronic lymphocytic leukemia cells. Experimental Hematology & Oncology
2013 2:23.
